Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1197-1206

  Matulis, Shannon M ^a   Morales, Alejo A ^a   Yehiayan, Lucy ^b   Croutch, Claire ^a   Gutman, Delia ^a   Cai, Yong ^b   Lee, Kelvin P ^c   Boise, Lawrence H ^a,d  

^a UNIVERSITY OF MIAMI   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d RMSB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; BH3 PROTEIN; BIM PROTEIN; BUTHIONINE SULFOXIMINE; CELL PROTEIN; CYSTEINE; CYSTEINE DERIVATIVE; DARINAPARSIN; DEXTRO CYSTEINE; GLUTATHIONE; GLUTATHIONE DERIVATIVE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN BMF; PROTEIN NOXA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ZIO 101;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MULTIPLE MYELOMA; OXIDES;

EID: 66849142003     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1072     Document Type: Article

References (33)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873
2. Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10:370-374 (Pubitemid 37296063)
3. Chng WJ, Lau LG, Noorainun Y, Mow BMF. Targeted therapy in multiple myeloma. Cancer Control 2005;12:91-104. (Pubitemid 40647052)
4. Hideshima T, Leif Bergsagel P, Kuel WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-618 (Pubitemid 38970551)
5. Rousselot P, Labaume S, Marolleau JP, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041-1048 (Pubitemid 29135964)
6. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813
7. Rousselot P, Larghero J, Arnulf B, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 2004;18:1518-1521 (Pubitemid 39264075)
8. Hussein MA, Saleh M, Ravandi R, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125:470-476 (Pubitemid 38916192)
9. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277 (Pubitemid 29019412)
10. Bahlis NJ, McCatterty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-3668 (Pubitemid 35424755)
11. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6:3-10. (Pubitemid 32405843)
12. Soignet SL, Tong WP, Hirschfeld S, Warrell RP, Jr. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999;44:417-421
13. Camacho LH, Hong D, Gutierrez C, et al. Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers [abstract]. J Clin Oncol 2006;24:6055.
14. Berenson JR, Jagannath S, Boccia R, et al. Phase 1/2 trials of dose and schedule of ZIO-101 (S-dimethylarsino-glutathione) in multiple myeloma [abstract]. Hematol J 2007;92:156. PO-609.
15. Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008;111:5152-5162
16. McCafferty-Grad J, Bahlis NJ, Krett N, et al. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003;2:1155-1164
17. West JD, Marnett LJ. Alterations in gene expression induced by the lipid peroxidation product, 4-hydroxy-2-nonenal. Chem Res Toxicol 2005;18:1642-1653 (Pubitemid 43257745)
18. Griffith OW. Biological and pharmacological regulation of mammalian glutathione synthesis. Free Radical Biol Med 1999;27:922-935 (Pubitemid 29507466)
19. Sakurai T, Kojima C, Kobayashi Y, et al. Toxicity of a trivalent organic arsenic compound dimethylarinous glutathione in rat liver cell line (TRL1215). Br J Pharmacol 2006;149:888-897 (Pubitemid 44851713)
20. Lichtlen P, Schaffner W. The "metal transcription factor" MTF-1: biological facts and medical implications. Swiss Med Wkly 2001;131:647-652
21. Daugaard M, Rohde M, Jaattela M. The heat shock protein family: highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007;581:3702-3710 (Pubitemid 47081009)
22. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-2918 (Pubitemid 38638852)
23. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M. Members of the heat-shock protein 70 family promotes cancer cell growth by distinct mechanisms. Genes Dev 2005;19:570-582. (Pubitemid 40314989)
24. Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol 2008;142:551-561
25. Giudice A, Montella M. Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention. BioEssays 2006;28:169-181 (Pubitemid 43294789)
26. D'Autreaux B, Toledano MB. ROS as signaling molecules: mechanisms that generate specificity in ROS homeostasis. Mol Cell Biol 2007;8:813-824 (Pubitemid 47462134)
27. Sasaki H, Sato H, Kuriyama-Matsumura K, et al. Electrophile response element-mediated induction of the cysteine/glutamate exchange transporter gene expression. J Biol Chem 2002;277:44765-44771 (Pubitemid 36159069)
28. Baysan A, Yel L, Gollapudi S, Su H, Gupta S. Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 2007;30:313-318
29. Rosen BP. Biochemistry of arsenic detoxification. FEBS Lett 2002;529:86-92. (Pubitemid 35283916)
30. 3-resistant and MRP1/ABCC1- overexpressing cell lines. Leukemia 2008:1-11.
31. Mivechi NF, Koong AC, Giaccia AJ, Hahn GM. Analysis of HSF-1 phosphorylation inA549 cells treated with a variety of stresses. Int J Hyperthermia 1994;10:371-379 (Pubitemid 24180925)
32. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-219 (Pubitemid 38167313)
33. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656 (Pubitemid 37328916)